Type 2 diabetes is a progressive disease; initially, inadequate β-cell compensation for the increased demand in insulin due to insulin resistance precipitates hyperglycaemia; subsequent deterioration in β-cell function (βCF) and mass underlies the progression from non-pharmacological treatment through monotherapy failure, to the need for combination treatments [1–4]. This evidence concerns the gene INS and type 2 diabetes mellitus.